Anzeige
Mehr »
Mittwoch, 15.10.2025 - Börsentäglich über 12.000 News
Milliardär-gestützt: Eine 10-Bagger-Goldaktie, die gerade erst durchstartet!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 850501 | ISIN: US1101221083 | Ticker-Symbol: BRM
Tradegate
15.10.25 | 19:36
37,350 Euro
-1,07 % -0,405
Branche
Pharma
Aktienmarkt
S&P 100
S&P 500
1-Jahres-Chart
BRISTOL-MYERS SQUIBB COMPANY Chart 1 Jahr
5-Tage-Chart
BRISTOL-MYERS SQUIBB COMPANY 5-Tage-Chart
RealtimeGeldBriefZeit
37,32537,43520:00
37,32537,43520:00
ACCESS Newswire
151 Leser
Artikel bewerten:
(0)

Bristol-Myers Squibb Company: Bristol Myers Squibb Foundation Announces $1 Million Donation to Patient Advocate Foundation

New contribution will help expand access to care by strengthening the Patient Advocate Foundation's capacity to deliver essential services and case management to vulnerable patients

NORTHAMPTON, MA / ACCESS Newswire / October 15, 2025 / The Bristol Myers Squibb Foundation (BMS Foundation), an independent charitable organization whose mission is to improve global health, recently announced a $1 million donation to the Patient Advocate Foundation. The Patient Advocate Foundation (PAF) is a national 501 (c)(3) non-profit organization that provides professional case management services and financial assistance free of charge to Americans with chronic, life threatening, and debilitating illnesses.

The $1 million donation from the BMS Foundation will enable PAF to expand its nationally recognized case management program. For nearly 30 years, PAF case managers have provided direct support to patients living with chronic and critical illnesses and their families. PAF assists in helping to manage healthcare access challenges, as well as insurance and affordability, with an intentional commitment to vulnerable and medically underserved communities.

PAF case managers help patients and their families maintain access to prescribed healthcare services and medications, navigate insurance barriers, find resources to support cost-of-living expenses during treatment, evaluate and sustain health insurance coverage, apply for disability and manage or reduce out-of-pocket medical and living expenses. In FY2025, PAF's case management provided direct support and intervention to 13,551 individuals, collectively living with 773 unique diseases, making 30 contacts per case to bring resolution and securing over $17 million in debt relief.

In honor of Global Patient Week at Bristol Myers Squibb (BMS), an annual, week-long event honoring inspiring patients who are at the heart of the missions of both BMS and the BMS Foundation, the BMS Foundation made a donation to the Patient Advocate Foundation, to help improve access to essential care for patients.

"The BMS Foundation's donation to the Patient Advocate Foundation reflects our deep commitment to increasing access to care for those who need it most," said Catharine Grimes, President of the Bristol Myers Squibb Foundation. "By strengthening PAF's capacity to help patients and caregivers navigate complex healthcare systems, we are empowering more people to overcome barriers to care and treatment. This partnership exemplifies the spirit of Global Patient Week-placing patients at the heart of our mission and advancing health equity through compassion, advocacy, and action."

"We are honored to be the recipient of this impactful donation," said Fran Castellow, MSEd, President, Operations of Patient Advocate Foundation. "The generous support from the Bristol Myers Squibb Foundation will have a profound impact on PAF's ability to expand our support to patients and families in need of case management support. Each year, we receive more than twice the number of requests for case management assistance than we are able to support. This funding will help us close that gap-enabling us to deliver critical case management services and personalized support to more individuals facing serious health challenges who need help navigating access and affordability challenges that threaten their health outcomes and overall well-being."

The BMS Foundation's vision is to ensure that all people, regardless of where they live, can achieve their best possible health. They are committed to establishing strategic partnerships to build strong, sustainable local healthcare systems, ultimately transforming how care is delivered and helping to ensure improved health now and in the future.

View additional multimedia and more ESG storytelling from Bristol-Myers Squibb Company on 3blmedia.com.

Contact Info:
Spokesperson: Bristol-Myers Squibb Company
Website: https://www.3blmedia.com/profiles/bristol-myers-squibb-company
Email: info@3blmedia.com

SOURCE: Bristol-Myers Squibb Company



View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/bristol-myers-squibb-foundation-announces-1-million-donation-to-patie-1087099

© 2025 ACCESS Newswire
Solarbranche vor dem Mega-Comeback?
Lange galten Solaraktien als Liebling der Börse, dann kam der herbe Absturz: Zinsschock, Überkapazitäten aus China und ein Preisverfall, der selbst Marktführer wie SMA Solar, Enphase Energy oder SolarEdge massiv unter Druck setzte. Viele Anleger haben der Branche längst den Rücken gekehrt.

Doch genau das könnte jetzt die Chance sein!
Die Kombination aus KI-Explosion und Energiewende bringt die Branche zurück ins Rampenlicht:
  • Rechenzentren verschlingen Megawatt – Solarstrom bietet den günstigsten Preis je Kilowattstunde
  • Moderne Module liefern Wirkungsgrade wie Atomkraftwerke
  • hina bremst Preisdumping & pusht massiv den Ausbau
Gleichzeitig locken viele Solar-Aktien mit historischen Tiefstständen und massiven Short-Quoten, ein perfekter Nährboden für Kursrebound und Squeeze-Rally.

In unserem exklusiven Gratis-Report zeigen wir dir, welche 4 Solar-Aktien besonders vom Comeback profitieren dürften und warum jetzt der perfekte Zeitpunkt für einen Einstieg sein könnte.

Laden Sie jetzt den Spezialreport kostenlos herunter, bevor die Erholung am Markt beginnt!

Dieses Angebot gilt nur für kurze Zeit – also nicht zögern, jetzt sichern!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.